title: Regulatory T cells in the immunodiagnosis and outcome of kidney allograft rejection.
abstract: Acute rejection (AR) is responsible for up to 12% of graft loss with the highest risk generally occurring during the first six months after transplantation. AR may be broadly classified into humoral as well as cellular rejection. Cellular rejection develops when donor alloantigens, presented by antigen-presenting cells (APCs) through class I or class II HLA molecules, activate the immune response against the allograft, resulting in activation of naive T cells that differentiate into subsets including cytotoxic CD8(+) and helper CD4(+) T cells type 1 (TH1) and TH2 cells or into cytoprotective immunoregulatory T cells (Tregs). The immune reaction directed against a renal allograft has been suggested to be characterized by two major components: a destructive one, mediated by CD4(+) helper and CD8(+) cytotoxic T cells, and a protective response, mediated by Tregs. The balance between these two opposite immune responses can significantly affect the graft survival. Many studies have been performed in order to define the role of Tregs either in the immunodiagnosis of transplant rejection or as predictor of the clinical outcome. However, information available from the literature shows a contradictory picture that deserves further investigation.
authors.affiliation: Division of Pharmacology, Department of Medicine of the Systems, University of Rome Tor Vergata Rome, Italy.
authors.forename: O
authors.initials: O
authors.lastname: Franzese
authors.forename: A
authors.initials: A
authors.lastname: Mascali
authors.forename: A
authors.initials: A
authors.lastname: Capria
authors.forename: V
authors.initials: V
authors.lastname: Castagnola
authors.forename: L
authors.initials: L
authors.lastname: Paganizza
authors.forename: N
authors.initials: N
authors.lastname: Di Daniele
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D002450:Cell Communication; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation; D011379:Prognosis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000473:pathology; D018417:Th1 Cells / Q000276:immunology* / Q000473:pathology; D018418:Th2 Cells / Q000276:immunology* / Q000473:pathology; D023001:Transplantation Tolerance; D014184:Transplantation, Homologous
chemical_list: D015415:Biomarkers